Blood Proteins Patents (Class 435/69.6)
-
Publication number: 20140329278Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: ApplicationFiled: March 21, 2014Publication date: November 6, 2014Applicant: Ablynx N.V.Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
-
Publication number: 20140328829Abstract: Disclosed is an AGR2 blocking monoclonal antibody, and in particular, a humanized monoclonal antibody for blocking AGR2. Also disclosed is a pharmaceutical composition containing the antibody and a method for preparing the same, and a use of the antibody in blocking tumor growth and metastasis.Type: ApplicationFiled: July 5, 2012Publication date: November 6, 2014Inventors: Dawei Li, Zhenghua Wu, Hao Guo, Qi Zhu, Dhahiri S. Mashausi
-
Publication number: 20140328751Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: April 9, 2014Publication date: November 6, 2014Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Ole Petter Veiby, John S. Babcook
-
Publication number: 20140328862Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.Type: ApplicationFiled: May 17, 2012Publication date: November 6, 2014Applicants: THE ROCKEFELLER UNIVERSITY, California Institute of TechnologyInventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
-
Publication number: 20140329279Abstract: Supplementation of the bioflavonoids such as epigallocatechin gallate, rutin, naringin, or genistein into mammalian cell culture media are shown to be effective in reduction of acidic species variants on recombinant antibodies. The demonstrated reduction in acidic species through the use of bioflavonoids, facilitates the manufacturing of a less heterogeneous product with potential improvements in antibody structure and function.Type: ApplicationFiled: May 6, 2014Publication date: November 6, 2014Inventors: Min Wang, Patrick M. Hossler, Sean W. McDermott, Christopher Racicot, Kofi Chemfe, John Fann
-
Publication number: 20140328851Abstract: Herein are described two antibodies that can inhibit CETP-lipoproteins interaction and CETP activity. Presently described are an antibody or fragment thereof capable of specifically binding to an epitope of the N-terminal or C-terminal domains of CETP and methods of using these antibodies for separation, identification, diagnosis and therapy.Type: ApplicationFiled: May 15, 2014Publication date: November 6, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Gang Ren, Lei Zhang
-
Publication number: 20140328849Abstract: The invention provides anti-CRTh2 antibodies and methods of using the same.Type: ApplicationFiled: March 14, 2014Publication date: November 6, 2014Applicant: GENENTECH, INC.Inventors: Karin REIF, Isidro HOTZEL, Jo-Anne S. HONGO, Tao HUANG, Yonglei SHANG, Meredith HAZEN
-
Publication number: 20140322755Abstract: The present disclosure provides a sophorolipid composition that can be used for inducing protein expression in a fermentation host. The sophorolipid composition described herein can be prepared from a natural sophorolipid mixture. Acid treatment of the natural sophorolipid mixture results in a mixture of monoacetylated, deacetylated, and/or diacetylated sophorolipids. The chemically modified sophorolipid composition, or isolated components of the chemically modified sophorolipid composition, can be used as inducers for protein production in filamentous fungi.Type: ApplicationFiled: June 25, 2012Publication date: October 30, 2014Inventor: Tom Tao Huang
-
Publication number: 20140322757Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.Type: ApplicationFiled: April 30, 2014Publication date: October 30, 2014Applicant: FIVE PRIME THERAPEUTICS, INC.Inventors: Justin Wong, Maximiliano Vasquez
-
Publication number: 20140322210Abstract: Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.Type: ApplicationFiled: December 5, 2012Publication date: October 30, 2014Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Minha Park
-
Publication number: 20140322220Abstract: The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: November 22, 2012Publication date: October 30, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Axel Harrenga, Charlotte Christine Kopitz, Stefanie Hammer, Frank Dittmer, Sven Golfier, Mark Trautwein, Sandra Bruder, Juergen Franz, Beatrix Stelte-Ludwig, Lars Linden, Ricarda Finnern, Simone Greven, Jan Tebbe
-
Publication number: 20140322221Abstract: The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.Type: ApplicationFiled: March 28, 2014Publication date: October 30, 2014Applicant: Genentech, Inc.Inventors: Kathy L. MILLER, Leonard G. PRESTA
-
Publication number: 20140322218Abstract: The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: January 27, 2014Publication date: October 30, 2014Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, Shawn Jeffries, Chadwick T. King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
-
Publication number: 20140322129Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Applicant: Genentech, Inc.Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
-
Publication number: 20140322217Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.Type: ApplicationFiled: January 14, 2014Publication date: October 30, 2014Applicant: Xencor, Inc.Inventors: Gregory MOORE, Matthew Bernett, Rumana Rashid, John Desjarlais
-
Publication number: 20140322756Abstract: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide.Type: ApplicationFiled: December 27, 2013Publication date: October 30, 2014Applicant: GENENTECH, INC.Inventors: W. Robert ARATHOON, Paul J. CARTER, Anne M. MERCHANT, Leonard G. PRESTA
-
Publication number: 20140322236Abstract: The present invention provides novel antibodies to human ADORA2A.Type: ApplicationFiled: March 18, 2014Publication date: October 30, 2014Applicant: SDIX, LLCInventors: Ross S. CHAMBERS, Michael C. BROWN, Dale V. ONISK, L. Joe STAFFORD, Fenglin YIN
-
Publication number: 20140322233Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: June 2, 2014Publication date: October 30, 2014Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
-
Patent number: 8871467Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: GrantFiled: June 5, 2013Date of Patent: October 28, 2014Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
-
Patent number: 8871714Abstract: The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.Type: GrantFiled: December 21, 2012Date of Patent: October 28, 2014Assignee: Novo Nordisk Health Care AGInventors: Gert Bolt, Claus Kristensen
-
Publication number: 20140315251Abstract: An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.Type: ApplicationFiled: July 8, 2014Publication date: October 23, 2014Inventors: Gary F. Bammert, Steven A. Dunham
-
Publication number: 20140315249Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.Type: ApplicationFiled: February 18, 2014Publication date: October 23, 2014Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Changlin DOU, Gang CHEN, James P. FANDL
-
Publication number: 20140315250Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.Type: ApplicationFiled: April 3, 2014Publication date: October 23, 2014Applicant: TEVA Biopharmaceuticals USA, Inc.Inventors: Rodger SMITH, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
-
Publication number: 20140314745Abstract: The instant invention relates to the field of protein production and in particular to controlled protein heterogeneity compositions and processes for controlling the heterogeneity of proteins expressed in host cells.Type: ApplicationFiled: February 28, 2014Publication date: October 23, 2014Applicant: ABBVIE INC.Inventors: Lisa M. Rives, Cornelia Bengea, Xiaobei Zeng
-
Publication number: 20140314779Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.Type: ApplicationFiled: March 14, 2014Publication date: October 23, 2014Applicant: GENENTECH, INC.Inventors: Natarajan VIJAYASANKARAN, Steven J. MEIER, Sharat VARMA, Yi YANG
-
Publication number: 20140315252Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21.Type: ApplicationFiled: November 21, 2012Publication date: October 23, 2014Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
-
Publication number: 20140315816Abstract: The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Publication number: 20140308281Abstract: The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.Type: ApplicationFiled: October 4, 2012Publication date: October 16, 2014Inventors: Sophie Brouard, Le Hoa Mai, Caroline Mary, Nicolas Poirier, Jean-Paul Soulillou, Bernard Vanhove
-
Publication number: 20140308285Abstract: Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.Type: ApplicationFiled: March 12, 2014Publication date: October 16, 2014Applicant: Amgen Inc.Inventors: Wei YAN, Martin J. PENTONY, Luis G. BORGES, Mark L. MICHAELS
-
Publication number: 20140309404Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to human BMP-6, compositions comprising such antibodies, or antigen-binding fragments thereof, and methods of using the same for treatment of anemia of chronic disease.Type: ApplicationFiled: June 26, 2014Publication date: October 16, 2014Inventors: Neungseon Steven Seo, Stephanie Marie Eaton Truhlar
-
Publication number: 20140308276Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.Type: ApplicationFiled: February 9, 2012Publication date: October 16, 2014Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
-
Publication number: 20140308273Abstract: Cell culture media are provided herein as are methods of using the media for cell culture and antibody production from cells. Compositions comprising antibodies and fragments thereof, produced by the methods herein are also provided.Type: ApplicationFiled: March 14, 2014Publication date: October 16, 2014Applicant: GENENTECH, INC.Inventors: Veronica CARVALHAL, Natarajan VIJAYASANKARAN, Lauren FEENEY, Thomas DIROCCO, Nathan MCKNIGHT
-
Publication number: 20140308301Abstract: Compositions including an antibody specific for CD44 are provided. These antibodies specifically bind to hematologic malignant cells. Methods to use the CD44 antibodies to target cells expressing CD44 for therapeutic and diagnostic purposes are also provided.Type: ApplicationFiled: October 26, 2012Publication date: October 16, 2014Inventors: Thomas J. Kipps, Suping Zhang, Christina C. Wu
-
Publication number: 20140308704Abstract: The present invention relates to a cell line in which an expression construct is introduced into a genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus E1 coding gene sequence of SEQ ID NO:1 operatively linked to the promoter. According to the present invention, the cell line of the present invention is a novel cell line which is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the present invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus.Type: ApplicationFiled: November 22, 2012Publication date: October 16, 2014Inventors: Seung Shin Yu, Chang-Wan Joo, Jin-A Chae, Yeon Suk Cha
-
Publication number: 20140308286Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: March 19, 2014Publication date: October 16, 2014Applicant: AbbVie Inc.Inventors: Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson, Maria C. Harris, Junjian Liu, Peter C. Isakson, Jijie Gu
-
Publication number: 20140308271Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.Type: ApplicationFiled: January 2, 2014Publication date: October 16, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: ANTOINE ATTINGER, JONATHAN ALBERT BACK, STANISLAS BLEIN, RAMI LISSILAA, DARKO SKEGRO
-
Publication number: 20140308201Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: March 11, 2014Publication date: October 16, 2014Applicant: NOVARTIS AGInventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
-
Publication number: 20140309405Abstract: The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses alanine aminotransferase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide.Type: ApplicationFiled: March 26, 2014Publication date: October 16, 2014Inventors: Hisahiro Tabuchi, Tomoya Sugiyama
-
Publication number: 20140308703Abstract: Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.Type: ApplicationFiled: May 29, 2014Publication date: October 16, 2014Inventors: David M. Goldenberg, Zhengxing Qu, Chien-Hsing Chang, Edmund A. Rossi, Jeng-Dar Yang, Diane Rossi
-
Publication number: 20140308209Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: November 15, 2012Publication date: October 16, 2014Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Publication number: 20140302049Abstract: Described herein are to antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies.Type: ApplicationFiled: October 31, 2012Publication date: October 9, 2014Inventors: Peter Chu, Xiangyang Tan, Weixing Yang, Christilyn Graff
-
Publication number: 20140301946Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: March 11, 2014Publication date: October 9, 2014Applicant: NOVARTIS AGInventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
-
Publication number: 20140302033Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.Type: ApplicationFiled: November 9, 2012Publication date: October 9, 2014Applicant: UCB PHARMA S.A.Inventors: Ralph Adams, Pavalli Bhatta, Sam Phillip Heywood, David Paul Humphreys
-
Publication number: 20140302024Abstract: Functionalized pentraxin-2 (PTX-2) protomers and functionalized PTX-2 pentamers, methods for preparing functionalized PTX-2 protomers and functionalized PTX-2 pentamers, pharmaceutical compositions including functionalized PTX-2 pentamers, and methods for using the same are described herein.Type: ApplicationFiled: March 24, 2014Publication date: October 9, 2014Applicant: PROMEDIOR, INC.Inventors: Mark L. Lupher, JR., W. Scott Willett
-
Publication number: 20140302021Abstract: Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.Type: ApplicationFiled: October 25, 2012Publication date: October 9, 2014Inventors: Patrick Garidel, Isaac Craig Henderson, Pamela Klein
-
Publication number: 20140302016Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.Type: ApplicationFiled: June 19, 2014Publication date: October 9, 2014Inventors: LINDA C. BURKLY, JANINE L. FERRANT-ORGETTAS, ELLEN A. GARBER, YEN-MING HSU, LIHE SU, FREDERICK R. TAYLOR, RALPH ADAMS, DEREK THOMAS BROWN, ANDREW GEORGE POPPLEWELL, MARTYN KIM ROBINSON, ANTHONY SHOCK, KERRY LOUISE TYSON
-
Publication number: 20140302559Abstract: In the method as reported herein the isolation of nucleic acid segments encoding antibody variable domains and the insertion of the isolated nucleic acid segments in eukaryotic expression plasmids is performed without the intermediate isolation and analysis of clonal intermediate plasmids. Thus, in the method as reported herein the intermediate cloning, isolation and analysis of intermediate plasmids is not required, e.g. by analysis of isolated transformed E. coli cells.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Applicant: HOFFMANN-LA ROCHE INC.Inventors: Simone Hoege, Erhard Kopetzki, Dominique Ostler, Stefan Seeber, Georg Tiefenthaler
-
Publication number: 20140302040Abstract: The present invention provides an antibody that recognizes a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 15 in the Sequence Listing and has an anti-arthritic function, or a functional fragment thereof.Type: ApplicationFiled: May 15, 2013Publication date: October 9, 2014Inventors: Satomichi Yoshimura, Tatsuya Kurihara, Kayoko Kawashima, Masato Hoshino, Kumiko Kadoshima, Maki Tsujimoto, Takako Kimura, Jun Hasegawa
-
Publication number: 20140302054Abstract: Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies.Type: ApplicationFiled: October 31, 2012Publication date: October 9, 2014Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Weixing Yang, Christilyn Graff
-
Publication number: 20140302064Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.Type: ApplicationFiled: March 7, 2014Publication date: October 9, 2014Applicant: Xencor, Inc.Inventor: Gregory Moore